eMedicine Specialties > Endocrinology > Thyroid

Hashimoto Thyroiditis: Differential Diagnoses & Workup

Author: Stephanie L Lee, MD, PhD, Fellow, Association of Clinical Endocrinology; Director of Thyroid Nodule and Cancer Center, Associate Chief, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center; Associate Professor, Department of Medicine, Boston University School of Medicine
Coauthor(s): Sylvester Odeke, MD, FACE, Clinical Assistant Professor of Medicine, Division of Endocrinology and Metabolism, The Brody School of Medicine at East Carolina University; Steven B Nagelberg, MD, Clinical Professor, Department of Medicine, Division of Endocrinology and Metabolism, Drexel University College of Medicine
Contributor Information and Disclosures

Updated: Apr 10, 2009

Differential Diagnoses

Euthyroid Sick Syndrome
Hypopituitarism (Panhypopituitarism)
Goiter
Polyglandular Autoimmune Syndrome, Type I
Goiter, Diffuse Toxic
Polyglandular Autoimmune Syndrome, Type II
Goiter, Lithium-Induced
Thyroid Lymphoma
Goiter, Nontoxic
Goiter, Toxic Nodular

Other Problems to Be Considered

The following autoimmune phenomena may occur or be found in association with Hashimoto's thyroiditis:

  • Addison disease
  • Alopecia areata, totalis, and universalis
  • Autoimmune gastritis (pernicious anemia)
  • Chronic active hepatitis
  • Idiopathic hypoparathyroidism
  • Polymyalgia rheumatica and giant cell arteritis
  • Primary biliary cirrhosis
  • Primary ovarian or testicular failure
  • Rheumatoid arthritis
  • Sjögren syndrome
  • Systemic lupus erythematosus
  • Systemic sclerosis (scleroderma)
  • Type 1 diabetes mellitus8
  • Vitiligo

Workup

Laboratory Studies

  • In the presence of suggestive symptoms and physical findings, a serum TSH test is needed for the diagnosis of primary hypothyroidism, and it serves to assess the functional status of the thyroid.
    • This is a sensitive test of thyroid function; levels are invariably raised in hypothyroidism due to Hashimoto's thyroiditis and in primary hypothyroidism of any cause.
    • The TSH level is also elevated in subclinical hypothyroidism and is usually the initial laboratory abnormality detected as the pituitary gland attempts to increase thyroid hormone production from the failing thyroid gland. The total T4 or free T4 usually remain within reference ranges in subclinical hypothyroidism.
    • The TSH level may also be elevated in the recovery phase of euthyroid sick syndrome.
    • In the outpatient setting, when there is no cause to suspect hypothalamic or pituitary disease and in the absence of nonthyroidal illness and of medications that suppress TSH production in the inpatient setting, a normal TSH level excludes primary hypothyroidism of any cause.
    • Medications that suppress TSH production include steroids, dopamine, dobutamine, and octreotide.
    • A free T4 is usually needed to correctly interpret the TSH in some clinical settings. A low total T4 or free T4 level in the presence of an elevated TSH level further confirms the diagnosis of primary hypothyroidism.
    • When a total T4 study, rather than a free T4 study, is performed, a T3 resin uptake helps to correct the total T4 and T3 values for protein binding, especially thyroid hormone–binding globulin (TBG) abnormalities, but the FT4 is typically the test of choice.
    • When the serum TSH and the free T4 levels are low in the outpatient setting, the case for central hypothyroidism is strengthened. However, in the acutely ill patient, nonthyroidal illness (euthyroid sick syndrome) is the more likely possibility. The TSH level cannot be reliably used in some clinical settings to distinguish central hypothyroidism from nonthyroidal illness. Physical findings suggestive of thyroid disease, as well as the presence of obvious or subtle clinical features of hypothyroidism, become pivotal in establishing the correct diagnosis. A low T3 level and a high reverse T3 level may be of additional help in the diagnosis of nonthyroidal illness.
    • T3 levels are most often maintained within reference ranges (even in the very late stages of hypothyroidism), and T3 measurement has little value in the diagnosis of hypothyroidism. Furthermore, T3 levels may be low in up to 70% of hospitalized patients without hypothyroidism or any thyroid disease, as is the case with nonthyroidal illness.
    • The presence of thyroid autoantibodies, typically anti-TPO and also anti-Tg antibodies, delineates the cause of hypothyroidism as Hashimoto's thyroiditis or its variant. However, 10-15% of patients with Hashimoto's thyroiditis may be antibody negative.

Imaging Studies

  • Although features of Hashimoto's thyroiditis are usually identifiable on an ultrasonogram, a thyroid ultrasonogram is usually not necessary for diagnosing the condition. However, it is useful for assessing thyroid size, echotexture, and most importantly, whether thyroid nodules are present. Ultrasonographic study aids in confirming the presence of a thyroid nodule, in defining a nodule as solid or cystic, and in defining features suggestive of malignancy, such as irregular margins, a poorly defined halo, microcalcification, and increased vascularity on Doppler interrogation. Ultrasonography is useful in facilitating fine-needle aspiration of nodules in general and, in particular, small or poorly defined nodules when indicated and in patients with distorted neck anatomy. A definite diagnosis of benign versus malignant thyroid lesion can be confirmed only by cytologic or histologic examination of thyroid tissue.
  • Iodine uptake and scan usually are not indicated for the diagnosis of Hashimoto's thyroiditis. The usefulness of radioactive iodine and scan is in classifying a nodule as either hot or cold. A cold thyroid nodule would indicate a higher risk for malignancy and therefore a need for fine-needle aspiration.

Other Tests

  • The following tests are not necessary for the diagnosis of primary hypothyroidism but may be performed to evaluate complications of hypothyroidism in some patients, when clearly indicated.
    • Complete blood count - Up to 30-40% of patients with hypothyroidism have anemia, usually from decreased erythropoiesis. In 15% of patients, the anemia is of the iron deficiency type with microcytosis and hypochromia. Although this can be a normocytic normochromic anemia, the most common morphologic abnormality is a macrocytic anemia that may be partially due to deficient vitamin B-12 and folate intake.
    • Total and fractionated lipid profile - Total cholesterol, low-density lipoprotein (LDL), and triglyceride levels may be elevated in hypothyroidism and may be responsive to levothyroxine replacement.
    • Basic metabolic panel - Glomerular filtration rate, renal plasma flow, and renal free water clearance are all decreased in hypothyroidism and may result in hyponatremia.
    • Creatine kinase - Creatine kinase levels, predominantly the MM isoenzyme from skeletal muscle and the aldolase enzyme, are frequently elevated in severe hypothyroidism.
    • Prolactin - Prolactin may be elevated in primary hypothyroidism. This is thought to be caused by overlap secretion due to stimulation of the lactotroph by the elevated TRH level. The decreased clearance of prolactin in hypothyroidism may also play a contributory role. The elevated prolactin level leads to decreased gonadotropin secretion and decreased responsiveness to GnRH. The result of this is anovulatory cycles with menstrual abnormalities, galactorrhea, and infertility in some patients.
  • Other studies may be performed in the evaluation of complications of primary hypothyroidism (when indicated). These tests are usually not performed and are not necessary in routine diagnosis or evaluation of hypothyroid patients.
    • Chest radiograph may show small pleural effusions.
    • Electrocardiogram (ECG) may show low-voltage QRS tracing, nonspecific ST-wave changes, and premature ventricular contractions. Prolongation of the QT interval with torsade de pointes and ventricular tachycardia may be noted.
    • Echocardiogram may show some pericardial effusion in severe cases of hypothyroidism.

Procedures

  • Perform fine-needle aspiration of any dominant or suspicious thyroid nodules to exclude malignancy or the presence of a thyroid lymphoma in fast-growing thyroid goiters.9

Histologic Findings

Hashimoto's thyroiditis is a histologic diagnosis. Typically, the thyroid gland shows diffuse lymphocytic and plasma cell infiltration with formation of lymphoid follicles from follicular hyperplasia and damage to the follicular basement membrane. Atrophy of the thyroid parenchyma is usually evident. Correlation with the presence of thyroid autoantibodies, namely anti-TPO and anti-Tg, is helpful in confirming the diagnosis.

More on Hashimoto Thyroiditis

Overview: Hashimoto Thyroiditis
Differential Diagnoses & Workup: Hashimoto Thyroiditis
Treatment & Medication: Hashimoto Thyroiditis
Follow-up: Hashimoto Thyroiditis
References
Further Reading

References

  1. Hadj-Kacem H, Rebuffat S, Mnif-Feki M, et al. Autoimmune thyroid diseases: genetic susceptibility of thyroid-specific genes and thyroid autoantigens contributions. Int J Immunogenet. Apr 2009;36(2):85-96. [Medline].

  2. Duntas LH. Environmental factors and autoimmune thyroiditis. Nat Clin Pract Endocrinol Metab. Aug 2008;4(8):454-60. [Medline].

  3. Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun. Mar 21 2009;[Medline].

  4. Fava A, Oliverio R, Giuliano S, et al. Clinical evolution of autoimmune thyroiditis in children and adolescents. Thyroid. Feb 18 2009;[Medline].

  5. Vanderpump MP, French JM, Appleton D. The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort. Clin Endocrinol (Oxf). Jan 1998;48(1):39-44. [Medline].

  6. Vanderpump MP, Tunbridge WM, French JM. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). Jul 1995;43(1):55-68. [Medline].

  7. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. Dec 2007;36(4):1051-66; x-xi. [Medline][Full Text].

  8. Huber A, Menconi F, Corathers S, et al. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev. Oct 2008;29(6):697-725. [Medline].

  9. Baloch ZW, LiVolsi VA. Fine-needle aspiration of the thyroid: today and tomorrow. Best Pract Res Clin Endocrinol Metab. Dec 2008;22(6):929-39. [Medline].

  10. Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, et al. REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab. Aug 2005;90(8):4946-54. [Medline][Full Text].

  11. [Best Evidence] Vestgaard M, Nielsen LR, Rasmussen AK, et al. Thyroid peroxidase antibodies in pregnant women with type 1 diabetes: impact on thyroid function, metabolic control and pregnancy outcome. Acta Obstet Gynecol Scand. 2008;87(12):1336-42. [Medline].

  12. Arafah BM. Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer. Ann Intern Med. Aug 15 1994;121(4):247-51. [Medline].

  13. Blackshear JL, Schultz AL, Napier JS. Thyroxine replacement requirements in hypothyroid patients receiving phenytoin. Ann Intern Med. Sep 1983;99(3):341-2. [Medline].

  14. Canaris GJ, Manowitz NR, Mayor G. The Colorado thyroid disease prevalence study. Arch Intern Med. Feb 28 2000;160(4):526-34. [Medline].

  15. Doniach D, Bottazzo GF, Russell RC. Goitrous autoimmune thyroiditis (Hashimoto's disease). Clin Endocrinol Metab. Mar 1979;8(1):63-80. [Medline].

  16. Doniach D, Hudson VR, Roitt IM. Human auto-immune thyroiditis: Clinical studies. Br Med J. 1960;365-74.

  17. Fowler PB, Swale J, Andrews H. Hypercholesterolaemia in borderline hypothyroidism. Stage of premyxoedema. Lancet. Sep 5 1970;2(7671):488-91. [Medline].

  18. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. Mar 7 1985;312(10):601-4. [Medline].

  19. Mandel SJ, Larsen PR, Seely EW. Increased need for thyroxine during pregnancy in women with primary hypothyroidism [see comments]. N Engl J Med. Jul 12 1990;323(2):91-6. [Medline].

  20. Rosenbaum RL, Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med. Jan 1982;96(1):53-5. [Medline].

  21. Singer PA, Cooper DS, Levy EG. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association [see comments]. JAMA. Mar 8 1995;273(10):808-12. [Medline].

  22. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. Jun 7 2000;283(21):2822-5. [Medline].

  23. Stone E, Leiter LA, Lambert JR. L-thyroxine absorption in patients with short bowel. J Clin Endocrinol Metab. Jul 1984;59(1):139-41. [Medline].

  24. Surks MI, Chopra IJ, Mariash CN. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA. Mar 16 1990;263(11):1529-32. [Medline].

  25. Tunbridge WM. The epidemiology of hypothyroidism. Clin Endocrinol Metab. Mar 1979;DA - 19790611(1):21-7. [Medline].

  26. Tunbridge WM, Brewis M, French JM. Natural history of autoimmune thyroiditis. Br Med J (Clin Res Ed). Jan 24 1981;282(6260):258-62. [Medline][Full Text].

Keywords

Hashimoto thyroiditis, Hashimoto’s thyroiditis, thyroid, hypothyroidism, TSH, hypothyroid, levothyroxine, thyroid disease, thyroid problemsgoiter, goiters, low thyroid, thyroxine, thyroid hormone, thyroiditis, thyroid treatment, hypothyroidism symptoms, T3 thyroid, T4 thyroid, thyroid disorders, thyroid-stimulating hormone, triiodothyronine, myxedema coma, chronic lymphocytic thyroiditis, struma lymphomatosa, autoimmune thyroid diseases, AITD

Contributor Information and Disclosures

Author

Stephanie L Lee, MD, PhD, Fellow, Association of Clinical Endocrinology; Director of Thyroid Nodule and Cancer Center, Associate Chief, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center; Associate Professor, Department of Medicine, Boston University School of Medicine
Stephanie L Lee, MD, PhD is a member of the following medical societies: American College of Endocrinology, American Thyroid Association, and Endocrine Society
Disclosure: Nothing to disclose.

Coauthor(s)

Sylvester Odeke, MD, FACE, Clinical Assistant Professor of Medicine, Division of Endocrinology and Metabolism, The Brody School of Medicine at East Carolina University
Sylvester Odeke, MD, FACE is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Endocrinology, and North Carolina Medical Society
Disclosure: Nothing to disclose.

Steven B Nagelberg, MD, Clinical Professor, Department of Medicine, Division of Endocrinology and Metabolism, Drexel University College of Medicine
Steven B Nagelberg, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, American Medical Association, Endocrine Society, and Pennsylvania Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Ghassem Pourmotabbed, MD†, Former Associate Professor, Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Tennessee School of Medicine and Health Science Center
Ghassem Pourmotabbed, MD† is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, and Endocrine Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Don S Schalch, MD, Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, University of Wisconsin Hospitals and Clinics
Don S Schalch, MD is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, Central Society for Clinical Research, and Endocrine Society
Disclosure: Nothing to disclose.

CME Editor

Mark Cooper, MBBS, PhD, FRACP, Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University
Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD, Professor of Medicine, St Louis University School of Medicine
George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.